[Information provided by:
ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]
|NCT01012609 : External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas|
|Ages||Min: 3 Years Max: 21 Years|
- Patients must have either (1) histologic proof of a high-grade astrocytoma reviewed
by a POETIC institutional pathologist or (2) a radiological diagnosis via MRI scan of
a typical diffuse pontine tumor made by a POETIC institutional neuroradiologist.
Patients with a radiological diagnosis via MRI scan of a typical diffuse pontine
tumor will be enrolled on the diffuse pontine tumor arm of the study regardless of
histology in cases that are biopsied. Note: For collaborating non-POETIC
institutions, the reviews may be done by an institutional
- Patients must begin study prescribed therapy within 42 days of neurosurgical
resection or biopsy of the tumor (high-grade astrocytoma patients) or radiological
diagnosis (diffuse pontine tumor patients).
- Age ? 3-years and < 22-years-old.
- Brain MRI (and any other studies done according to clinical indications) must not
show any definitive evidence of leptomeningeal or extra-neural metastases.
- ANC ? 1000/?L and platelet count ? 100,000/?L
- Patients must have adequate organ function as defined by:
- Hepatic: total bilirubin < 1.5 mg/dl, AST ? 2.5 x the upper limit of normal.
- Renal: serum creatinine ? 1.5 x the upper limit of normal for age, or calculated
creatinine clearance or nuclear GFR ? 70 ml/min/1.73 m2.
- The patient, or for minors, a parent or legal guardian, must give informed written
consent indicating they are aware of the investigational nature of this study.
- Evidence of leptomeningeal or extra-neural metastatic disease.
- Prior radiation therapy or chemotherapy
- Pregnancy, mothers unwilling to refrain from breast-feeding, and sexually mature
patients unwilling to practice an effective form of birth control.
- Other significant concomitant medical illnesses that would compromise the patient's
ability to receive all prescribed study therapy.
- Prior therapy which specifically and directly targets the EGFR pathway.
- Prior severe infusion reaction to a monoclonal antibody.
- Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension,
unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled
congestive heart failure, and cardiomyopathy with decreased ejection fraction.
- Patients with known Gilbert's Syndrome.
|Links||Permanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01012609
| Link to official Clinicaltrials.gov listing